ABEO:
Yes on following them and them needing cash soon.
Management (3rd rendition) has not done well thus far (telling story, executing, creating value, strengthening balance sheet...)
Assets/Valuation: I think they have a good mix of assets priced as cheaply as any gene therapy company one could find probably because of a management/financing discount. Their MPS IIIA + EB get all the publicity but the jewel could turn out to be their CF program and perhaps some differentiated vectors from their library.
They could announce a deal to relieve some of the financings overhang. The chairman owns a ton of shares or I'd be more worried about one of those 100% dilutive toxic financings though I guesss that can't be totally ruled out.
Any specific questions? I'm not on I-hub too much these days you could try ask on Twitter for a quicker reply (@MauriceOnTW).
News 
Market Data 
Discover 
